Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2019 6
2020 3
2021 7
2022 5
2023 3
2024 3
2025 5
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025.
Rose AM, Lucaccioni H, Marsh K, Kirsebom F, Whitaker H, Emborg HD, Bolt Botnen A, O'Doherty MG, Pozo F, Hameed SS, Andrews N, Hamilton M, Trebbien R, Lauenborg Møller K, Marques DF, Murphy S, McQueenie R, Lopez-Bernal J, Cottrell S, Bucholc M, Kissling E; European IVE group; Members of the European IVE group. Rose AM, et al. Euro Surveill. 2025 Feb;30(7):2500102. doi: 10.2807/1560-7917.ES.2025.30.7.2500102. Euro Surveill. 2025. PMID: 39980423 Free PMC article.
COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network.
Laniece Delaunay C, Verdasca N, Monge S, Domegan L, Sève N, Buda S, Meijer A, Lucaccioni H, López Torrijos M, McKenna A, Enouf V, Dürrwald R, In't Velt E, de Valcárcel Laiglesia MÁ, Bennett C, Masse S, Erdwiens A, Hooiveld M, Mlinarić I, Túri G, Rodrigues AP, Martínez-Baz I, Lazar M, Latorre-Margalef N, Borges V, Kaczmarek M, Bacci S, Kissling E; European primary care VE group. Laniece Delaunay C, et al. Among authors: masse s. Influenza Other Respir Viruses. 2025 May;19(5):e70120. doi: 10.1111/irv.70120. Influenza Other Respir Viruses. 2025. PMID: 40395132 Free PMC article.
Serological evaluation of Crimean-Congo Hemorrhagic fever in humans with High-Risk professional exposure and in residual sera collected in 2022-2023 across Corsica (France).
Kiwan P, Gasparine M, Decarreaux D, Capai L, Masse S, Korva M, Avšič-Županc T, Canarelli J, Simeoni MH, de Lamballerie X, Charrel R, Falchi A. Kiwan P, et al. Among authors: masse s. One Health. 2025 Mar 25;20:101020. doi: 10.1016/j.onehlt.2025.101020. eCollection 2025 Jun. One Health. 2025. PMID: 40230584 Free PMC article.
Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24.
Kissling E, Maurel M, Pozo F, Pérez-Gimeno G, Buda S, Sève N, Domegan L, Hooiveld M, Oroszi B, Martínez-Baz I, Guiomar R, Latorre-Margalef N, Mlinarić I, Lazar M, Giménez Duran J, Dürrwald R, Enouf V, McKenna A, de Lange M, Túri G, Trobajo-Sanmartín C, Gomez V, Samuelsson Hagey T, Višekruna Vučina V, Cherciu MC, García Vazquez M, Erdwiens A, Masse S, Bennett C, Meijer A, Kristóf K, Castilla J, Rodrigues AP, Kurečić Filipović S, Ivanciuc AE, Bacci S, Kaczmarek M; European primary care VE group. Kissling E, et al. Among authors: masse s. Euro Surveill. 2025 Jun;30(23):2500011. doi: 10.2807/1560-7917.ES.2025.30.23.2500011. Euro Surveill. 2025. PMID: 40511473 Free PMC article.
Influenza vaccine effectiveness from nine studies during drifted A(H3N2) subclade K predominance, Europe, September 2025 to January 2026.
Lucaccioni H, Marques DF, Kirsebom F, Emborg HD, Hamilton M, Whitaker H, Bolt Botnen A, Bucholc M, Pozo F, Andrews N, Trebbien R, Hameed SS, Lauenborg Møller K, O'Doherty MG, Lopez-Bernal J, Morrison K, Cottrell S, Wilton S, Rose AM, Kissling E; European IVE group. Lucaccioni H, et al. Euro Surveill. 2026 Feb;31(7):2600109. doi: 10.2807/1560-7917.ES.2026.31.7.2600109. Euro Surveill. 2026. PMID: 41716088 Free PMC article.
Eight Months of Serological Follow-Up of Anti-SARS-CoV-2 Antibodies in France: A Study among an Adult Population.
Decarreaux D, Sevila J, Masse S, Capai L, Fourié T, Villarroel PMS, Amroun A, Nurtop E, Vareille M, Blanchon T, de Lamballerie X, Charrel R, Falchi A. Decarreaux D, et al. Among authors: masse s. Int J Environ Res Public Health. 2022 Nov 18;19(22):15257. doi: 10.3390/ijerph192215257. Int J Environ Res Public Health. 2022. PMID: 36429974 Free PMC article.
COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans.
Laniece Delaunay C, Mazagatos C, Martínez-Baz I, Túri G, Goerlitz L, Domegan L, Meijer A, Rodrigues AP, Sève N, Ilic M, Latorre-Margalef N, Lazar M, Maurel M, Melo A, Andreu Ivorra B, Casado I, Horváth JK, Buda S, Bennett C, de Lange M, Guiomar R, Enouf V, Mlinaric I, Samuelsson Hagey T, Dinu S, Rumayor M, Castilla J, Oroszi B, Dürrwald R, O'Donnell J, Hooiveld M, Gomez V, Falchi A, Kurecic Filipovic S, Dillner L, Popescu R, Bacci S, Kaczmarek M, Kissling E; VEBIS Primary Care Vaccine Effectiveness Group. Laniece Delaunay C, et al. JAMA Netw Open. 2024 Jul 1;7(7):e2419258. doi: 10.1001/jamanetworkopen.2024.19258. JAMA Netw Open. 2024. PMID: 38949812 Free PMC article.
What is the relevancy of a surveillance of mumps without a systematic laboratory confirmation in highly immunized populations? Epidemiology of suspected and biologically confirmed mumps cases seen in general practice in France between 2014 and 2020.
Prévot-Monsacré P, Hamaide-Defrocourt F, Guyonvarch O, Masse S, Souty C, Mamou T, Hamel J, Antona D, Mathieu P, Vasseur P, Lévy-Bruhl D, Baroux N, Rossignol L, Vaillant L, Guerrisi C, Hanslik T, Dina J, Blanchon T. Prévot-Monsacré P, et al. Among authors: masse s. Vaccine. 2024 Feb 15;42(5):1065-1070. doi: 10.1016/j.vaccine.2023.12.017. Epub 2023 Dec 12. Vaccine. 2024. PMID: 38092609 Free article.
37 results